ACM
NBIX icon

Asymmetry Capital Management’s Neurocrine Biosciences NBIX Stock Holding History

Asymmetry Capital Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-20,571
Closed -$1.47M – 32
2018
Q4 		$1.47M Sell
20,571
-2,562
-11% -$245K 4.06% 9
2018
Q3 		$2.84M Sell
23,133
-3,777
-14% -$429K 2.63% 16
2018
Q2 		$2.64M Sell
26,910
-2,915
-10% -$261K 2.6% 15
2018
Q1 		$2.47M Buy
29,825
+5,030
+20% +$425K 3.09% 11
2017
Q4 		$1.92M Sell
24,795
-26,702
-52% -$1.82M 2.61% 13
2017
Q3 		$3.16M Buy
51,497
+17,467
+51% +$922K 3.66% 11
2017
Q2 		$1.56M Buy
+34,030
New +$1.65M 1.86% 21
2016
Q4 		– Sell
-37,644
Closed -$1.91M – 23
2016
Q3 		$1.91M Buy
37,644
+6,973
+23% +$347K 3.31% 12
2016
Q2 		$1.39M Sell
30,671
-32,517
-51% -$1.5M 2.55% 17
2016
Q1 		$2.5M Buy
63,188
+22,300
+55% +$885K 6.51% 6
2015
Q4 		$2.31M Sell
40,888
-8,612
-17% -$438K 3.5% 11
2015
Q3 		$1.97M Buy
+49,500
New +$2.39M 4.39% 10

Other funds holding NBIX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Asymmetry Capital Management's NBIX Position: Q1 2019 in Review

Asymmetry Capital Management sold out of Neurocrine Biosciences (NBIX) in Q1 2019, closing a stake of 20,571 shares — an estimated $1.47M sold.

Asymmetry Capital Management first reported a position in NBIX in Q3 2015 and held it in 12 quarters. The position peaked at $3.16M in Q3 2017. 325 funds tracked by Wall St. Rank hold NBIX as of Q1 2019.

  • Asymmetry Capital Management reported no remaining Neurocrine Biosciences position as of Q1 2019 after selling out during the quarter.
  • Asymmetry Capital Management sold 20,571 Neurocrine Biosciences shares in Q1 2019, an estimated $1.47M.
  • Asymmetry Capital Management first reported a position in Neurocrine Biosciences in Q3 2015 and held it in 12 quarters.
  • Asymmetry Capital Management's Neurocrine Biosciences position peaked at $3.16M in Q3 2017.
  • 325 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2019.

Based on Asymmetry Capital Management's 13F filing for Q1 2019, filed 8 May 2019.